NASDAQ : ROIV
Roivant Sciences Ltd. — Key statistics
Healthcare · Biotechnology · United Kingdom
Last price 36.91 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 26.66B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 25.92B |
| Enterprise Value | 22.19B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 9, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 722.32M |
| Shares Outstanding | 722.32M |
| Shares Change (YoY) | -1.06% |
| Shares Change (QoQ) | -11.27% |
| Owned by Insiders (%) | 18.67% |
| Owned by Institutions (%) | 79.48% |
| Float | 582.40M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3,441.87 |
| Forward PS | 235.03 |
| PB Ratio | 6.13 |
| P/TBV Ratio | 6.13 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 2,946.00 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 16.72 |
| Quick Ratio | 13.62 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -8.52% |
| Return on Assets (ROA) | -16.28% |
| Return on Invested Capital (ROIC) | -117.33% |
| Return on Capital Employed (ROCE) | -26.80% |
| Weighted Average Cost of Capital (WACC) | 10.27% |
| Revenue Per Employee | $10,447 |
| Profits Per Employee | -$369,283 |
| Employee Count | 721 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | 124.72M |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.10 |
| 52-Week Price Change | +79.54% |
| 50-Day Moving Average | 36.64 |
| 200-Day Moving Average | 31.57 |
| Relative Strength Index (RSI) | 48.68 |
| Average Volume (20 Days) | 6,649,814 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 40.30M |
| Short Previous Month | 39.30M |
| Short % of Shares Out | 5.58% |
| Short % of Float | 6.92% |
| Short Ratio (days to cover) | 5.65 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 7.53M |
| Gross Profit | -723.89M |
| Operating Income | -1.35B |
| Pretax Income | -289.88M |
| Net Income | -266.25M |
| EBITDA | -1.34B |
| EBIT | -1.35B |
| Loss Per Share | -$0.49 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 3.84B |
| Total Debt | 107.15M |
| Net Cash | 3.73B |
| Net Cash Per Share | $5.17 |
| Equity (Book Value) | 4.92B |
| Book Value Per Share | 5.86 |
| Working Capital | 4.46B |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -816.47M |
| Capital Expenditures | -4.59M |
| Depreciation & Amortization | 2.85M |
| Net Borrowing | n/a |
| Free Cash Flow | -821.06M |
| FCF Per Share | -$1.14 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | -17,875.42% |
| Pretax Margin | -3,848.65% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | 1.06% |
| Shareholder Yield | 1.06% |
| Earnings Yield | -1.36% |
| FCF Yield | -3.17% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $50.00 |
| Price Target Difference | 39.32% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 13 |
| Revenue Growth Forecast (3Y) | 479.14% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 23.81 |
| Piotroski F-Score | n/a |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |